Rubius Therapeutics logo

Rubius Therapeutics

Pioneering the creation of ready to use red cell therapies for the treatment of severe diseases Rubius Therapeutics is developing RCTs_ as a new class of advanced cellular therapies by reprograming the inherent properties of red cells through genetic engeneering and is developing Red-Cell Therapeutics (RCTs) as a new treatment modality to address a wide array of indications including autoimmune, metabolic and other diseases.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”RUBY” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.rubiustx.com
Founded2014
Disease Focus
Development Stage
STOCK CODENASDAQ: RUBY
Address
325 Vassar Street Suite 1A, MA 02139
Cambridge
United States
Email
Contact Number
+1 617-218-1606

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/rubius-therapeutics” connections=”true” suffix=””]

Rubius has proprietary RED PLATFORM_ to develop Red-Cell Therapeutics_ (RCT_) products which are genetically engineered, enucleated red cells that are being developed to provide allogeneic, ready-to-use cellular therapies to patients. Single O- blood donor can generate enough doses to potentially treat hundreds to thousands of individual patients. Rubius is developing a pipeline of RCTs to target, starve, penetrate and destroy cancer cells, by targeting T cells, NK cells, dendritic cells and tumor cells.

In Mar 2018, Rubius Therapeutics raised $100 Mn in a highly oversubscribed crossover financing to further support manufacturing and clinical development of novel red-cell therapeutics. Earlier in June 2017, Rubius raised $120 Mn in an oversubscribed private financing round.